Neuroblastoma

TNP-470 Prevents Growth In Murine Model

Published in Cancer Weekly, May 15th, 2001

by Sonia Nichols, senior medical writer - A growing body of evidence supports the premise that TNP-470 is a potent angiogenesis inhibitor in tumors. Researchers in Philadelphia, Pennsylvania, have provided further evidence by demonstrating that TNP-470 inhibits angiogenesis in neuroblastomas.

Authors of this new study tested TNP-470 on mice inoculated with neuroblastoma cells. Their results, reported in Clinical Cancer Research, show TNP-470 as a strong angiogenesis inhibitor when administered by continuous infusions or during intermittent dosing.

"Treatment was given as a single agent in established xenografts, 10 days after 450 mg/kg of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry